title: Development of an in vitro fibrin clot model to evaluate fibrinolytic agents for wound care application.
abstract: OBJECTIVE
  To describe an in vitro fibrin clot model that could reliably assess the fibrinolytic activity of enzymatic debriding agents for wound care application.
  
  
  METHODS
  A model of a fibrin clot was reconstructed in vitro by mixture of human fibrinogen and (alpha)-thrombin supplemented with factor XIII. These clots were then treated with enzymatic ointments. Fibrinolytic activity was investigated by measuring D-dimer levels, using an automated immunoturbidimetric Liatest D-dimer assay.
  
  
  RESULTS
  Collagenase and papain-urea ointments demonstrated fibrinolytic activity which was macroscopically visible. Their effect was identical on the in vitro reconstructed fibrin clot and ex vivo collected wound fibrin clot; collagenase and papain-urea both induced a complete degradation and dissolution of both fibrin clots after 24 hours of treatment. This was associated with an increase in D-dimer concentration.
  
  
  CONCLUSIONS
  This reconstructed fibrin clot in vitro model has the potential to predict the efficacy of fibrinolytic agents and therefore appears to be a suitable model for in vitro assays.
  
  
  BACKGROUND
  This study was supported by a grant from URGO Laboratory.
authors: PhD, Research Engineer, Engineering and Cutaneous Biology Laboratory, UMR 1098, University of Franche-Comte, France.
authors: C
authors: C
authors: Viennet
authors: Industrial Pharmacist, URGO Laboratory, France.
authors: C
authors: C
authors: Laurensou
authors: Research Technician, Engineering and Cutaneous Biology Laboratory, UMR 1098, University of Franche-Comte, France.
authors: A C
authors: AC
authors: Goydadin
authors: MD, Dermatologist, Department of Dermatology, Besançon University Hospital, France.
authors: B
authors: B
authors: Faivre
authors: MD, PhD, Hospital Practitioner, Engineering and Cutaneous Biology Laboratory, UMR 1098, University of Franche-Comte, France, Department of Clinical Pharmacology, Besançon University Hospital, France.
authors: P
authors: P
authors: Muret
authors: MD, PhD, Professor of Dermatology, Engineering and Cutaneous Biology Laboratory, UMR 1098, University of Franche-Comte, France, Department of Dermatology, Besançon University Hospital, France.
authors: P
authors: P
authors: Humbert
mesh_terms: D017364:Collagenases / Q000494:pharmacology*; D005337:Fibrin / Q000378:metabolism*; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D010206:Papain / Q000494:pharmacology*; D013917:Thrombin / Q000378:metabolism; D014508:Urea / Q000494:pharmacology*; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; C036309:fibrin fragment D; D014508:Urea; D005337:Fibrin; D005340:Fibrinogen; D013917:Thrombin; D010206:Papain; D017364:Collagenases